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Abstract
Background: There is consensus that experimental autoimmune encephalomyelitis (EAE) can be mediated by myelin
specific T cells of Th1 as well as of Th17 phenotype, but the contribution of either subset to the pathogenic process has
remained controversial. In this report, we compare functional differences and pathogenic potential of ‘‘monoclonal’’ T cell
lines that recognize myelin oligodendrocyte glycoprotein (MOG) with the same transgenic TCR but are distinguished by an
IFN-c producing Th1-like and IL-17 producing Th17-like cytokine signature.
Methods and Findings: CD4+ T cell lines were derived from the transgenic mouse strain 2D2, which expresses a TCR
recognizing MOG peptide 35–55 in the context of I-Ab. Adoptive transfer of Th1 cells into lymphopenic (Rag22/2) recipients,
predominantly induced ‘‘classic’’ paralytic EAE, whereas Th17 cells mediated ‘‘atypical’’ ataxic EAE in approximately 50% of
the recipient animals. Combination of Th1 and Th17 cells potentiated the encephalitogenicity inducing classical EAE
exclusively. Th1 and Th17 mediated EAE lesions differed in their composition but not in their localization within the CNS.
While Th1 lesions contained IFN-c, but no IL-17 producing T cells, the T cells in Th17 lesions showed plasticity, substantially
converting to IFN-c producing Th1-like cells. Th1 and Th17 cells differed drastically by their lytic potential. Th1 but not Th17
cells lysed autoantigen presenting astrocytes and fibroblasts in vitro in a contact-dependent manner. In contrast, Th17 cells
acquired cytotoxic potential only after antigenic stimulation and conversion to IFN-c producing Th1 phenotype.
Conclusions: Our data demonstrate that both Th1 and Th17 lineages possess the ability to induce CNS autoimmunity but
can function with complementary as well as differential pathogenic mechanisms. We propose that Th17-like cells producing
IL-17 are required for the generation of atypical EAE whereas IFN-c producing Th1 cells induce classical EAE.
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Introduction
Experimental Autoimmune Encephalomyelitis (EAE), an ani-
mal model representing human multiple sclerosis (MS), is
mediated by CD4+ helper T cells which trigger an (auto)-
inflammatory response against central nervous system (CNS)
structures that culminates in demyelination, axonal damage and
paralysis. Over decades, IFN-c secreting Th1 cells primed by a
heterodimeric cytokine IL-12 were considered to be the only
effector T cells inducing EAE. Paradoxically, however, mice
deficient of either IFN-c [1], IL-12 p35 subunit [2] or their
corresponding receptors IFN-cR [3] and IL-12Rb2 [4] were not
protected, but highly susceptible to EAE induction. In contrast,
mice treated with antibodies neutralizing the IL-12 p40 subunit, or
mutant mice lacking IL-12 p40 subunit were resistant to EAE
induction [5–8]. Cua et al. explained this paradox by the double
usage of the IL-12 p40 subunit by both IL-12 and IL-23
(heterodimer of IL-12p40 and IL-23p19 subunits). In fact, this
work demonstrated that IL-12 specific p35, but not IL-23 specific
p19, is dispensable for EAE development [9]. IL-23 was shown to
drive the maintenance and expansion of a distinct and newly
identified CD4+ helper T cell subset, Th17 cells, which produced
abundant amounts of IL-17 instead of IFN-c [10].
Initially these findings seemed to suggest that Th17 cells but not
Th1 cells were the only pathogenic effector cells in EAE. These
conclusions were mainly drawn from studies of EAE actively
induced by immunization with complete Freund’s adjuvant, a
harsh treatment that profoundly impacts the general immune
response. More recently, however, studies of adoptive transfer
EAE using polarized Th1 and Th17 cells support pathogenic roles
for either subset. But some of the findings remained contradictory.
O’Connor and colleagues demonstrated that MOG specific Th1
cells are highly pathogenic, and are required to facilitate entry of
Th17 cells into CNS lesions [11]. Using MOG-specific transgenic
T cells, Yang et al found that T-bet expression was essential for
EAE induced by Th1 and Th17 cells [12]. Recently, another study
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proposed that the ratio of myelin-specific Th17 versus Th1 cells
determines the site of CNS inflammation [13]. Similarly, both IL-
12 and IL-23 driven myelin-reactive T cells were found to induce
distinct clinical EAE outcomes [14]. Finally, in spontaneous
mouse EAE models with different genetic backgrounds CNS
lesions contained both Th1 and Th17 cells, suggesting that both
T cell lineages participate in the autoimmune pathogenesis
[15,16].
In the present study, we searched for functional differences and
pathogenic potential of the ‘‘monoclonal’’ MOG-specific CD4+ T
cells with Th1- and Th17-like functional profiles. These were
derived from MOG-specific TCR transgenic (2D2) mice with
C57BL/6 genetic background. When adoptively transferred into
lymphopenic hosts, either individually or combined, both Th1 and
Th17 cells per se were capable of inducing EAE, but combinations
of Th1 and Th17 cells displayed a potentiated effect. The clinical
disease mediated by either CD4+ T cell lineage differed
profoundly. While Th1 cells mediated classic EAE with hind limb
paralysis, Th17 cells transferred a disease with ataxic gait in
approximately half of the animals. Within the CNS infiltrates,
Th17 cells seemed to convert to a Th1 phenotype, but not vice-
versa. Finally, Th1 cells differed from Th17 cells by their cytotoxic
potential. They lysed antigen presenting astrocytes in in vitro co-
cultures, an activity not seen with Th17 cells.
Results
Differentiation and functional characterization of MOG-
specific Th1 and Th17 cells
We used 2D2 TCR transgenic T cells that recognize MOG [17]
to obtain sufficient numbers of Th1 and Th17 cells. We optimized
in vitro differentiation protocols for Th1 and Th17 cells as
described in methods. With this protocol, we obtained bulk
numbers of Th1 and Th17 cells largely free of contaminating IL-
17 and IFN-c producing cells in Th1 and Th17 polarizations,
respectively (Figure 1). In Th1 cultures, we consistently obtained
more than 50% of T cells that produced IFN-c and in Th17
cultures 20–50% of cells produced IL-17. More than 90% of these
cells expressed the Va3.2/Vb11 transgenic TCR chains
(Figure 1A). ELISA results confirmed that Th1 cells produced
IFN-c and Th17 cells produced large amounts of IL-17 in a
mutually exclusive manner (Figure 1B). Also, mRNA of the
signature transcription factors for Th1 and Th17 cells, T-bet and
RORct respectively, together with IFN-c and IL-17 were
expressed selectively in their corresponding T cell subset
(Figure 1C).
To further understand the functional differences of Th1 and
Th17 cells, we measured the expression of a panel of cytokines and
activation markers. Both Th1 and Th17 cells did not produce
appreciable levels of Th2-related cytokines IL-4 and IL-5 whereas
they produced comparable amounts of anti-inflammatory cytokine
IL-10 (Figure 2A). GM-CSF, an important pro-inflammatory
cytokine found to be important in EAE pathogenesis, was
exclusively expressed by Th1 cells (Figure 2B). The activation
status of Th1 and Th17 cells was evaluated by flow cytometry.
Th1 and Th17 cells markedly differed in the expression of the
characteristic cell surface activation markers CD62L and CD25.
While all Th17 cells were CD62Llow, only about 50% of Th1 cells
downregulated this receptor. On the other hand, Th17 cells did
not express CD25, as did Th1 cells (Figure 2C). Finally, the
antigen-specific reactivity of MOG-specific polarized Th1 and
Th17 cells was measured by a proliferation assay. Th17 cells
exhibited a higher proliferative response than Th1 cells in response
to their cognate antigen, MOG (Figure 2D).
Both Th1 and Th17 cells induce EAE, but with different
clinical phenotype
We compared the encephalitogenic potential of MOG-specific
Th1 and Th17 cell subsets in EAE by adoptive transfer. Three days
after secondary in vitro stimulation in polarizing conditions, we
transferred activated T cell blasts either individually or in
combination into Rag22/2 recipient mice. The use of lymphopenic
recipients allowed us to evaluate the pathogenic potential of these
CD4+ helper T cell subsets in the absence of host derived T and B
cells. In this model, we observed 100% EAE incidence with similar
day of disease onset, between 11 and 18 days post-transfer, in both
Th1 and Th17 cells recipient animals. Interestingly, co-transfer of
Th1 and Th17 cells induced EAE with earlier onset, between 10
and 13 days post-transfer, with severe disease (Figures 3A, B).
Th1 cells or Th1/Th17 co-transfers induced classical EAE in
almost all recipients, characterized by a paralysis progressing from
tail to head. In contrast, approximately 50% of Th17 cells
recipients came down with an atypical neurological disease
exhibiting an ataxia with an unbalanced gait and in few mice
severe axial and barrel rotatory defects (Figure 3C, Video S1).
Mice that recovered from such an ataxia eventually developed
classical EAE symptoms such as paralysis. We compared CNS
lesions of sick mice from all the adoptive transfer groups at the
peak of the disease. Histological and immunohistochemistry
analysis revealed that all groups exhibited severe immune cells
infiltration (CD4+ T cells and macrophages), astrogliosis, microglia
activation, demyelination and axonal damage. However, this was
largely indistinguishable between Th1 and Th17 single transfers or
between Th17 classic and ataxic EAE. Lesions were located
throughout the CNS in both Th1 and Th17 recipients, with no
significantly different preferential localization of CD4+ T cell
infiltrates. In addition, we found infiltration and demyelination in
the PNS, in particular the trigeminal root and the spinal roots in
both groups (Table 1, Figure S2 and data not shown).
Plasticity of Th17 cells in vivo
We analyzed the cellular composition of CNS infiltrating
mononuclear cells as well as peripheral lymphoid organs of
Rag22/2 recipients. Mice at the peak of paralytic or ataxic EAE
had major infiltrates in both brain and spinal cord. Flow cytometric
analysis for the intracellular cytokines showed that Th1 recipients
contained mainly IFN-c and negligible numbers of IL-17 producing
CD4+ T cells in both brain and spleen. In contrast, mice with Th17
mediated EAE had both IFN-c and IL-17 producing CD4+ T cells
in similar proportions. In addition, we found IFN-c+ IL-17+ double
positive CD4+ T cell population in the CNS but not in the
periphery of Th17 recipients (Figure 4A). Analysis of spinal cord
and lymph nodes yielded similar results (data not shown).
The co-existence of IFN-c+ and IFN-c+ IL-17+ double positive
cells in the CNS of Th17 recipient mice might suggest a possible
conversion of Th17 cells to the Th1 phenotype or de novo induction
from double negative cells in vivo. Since IFN-c is a negative
regulator of Th17 polarization, we hypothesized that IFN-c
produced by cells of the local milieu could have initiated this
conversion. To neutralize such signals, we treated Th17 cell
recipients with a blocking antibody for IFN-c. However, such
treatment had no effect on EAE onset or severity and majority of
the treated mice developed atactic phenotype similar to untreated
Th17 cells recipients (Figure 3). More important, T cell
conversion from Th17 to a Th1 phenotype was not impaired by
blocking IFN-c (Figure 4A). The expression levels of IFN-c and
IL-17 in the brains of Rag22/2 recipients after transfer of Th1,
Th17, mixture of Th1 and Th17 cells or Th17 cells and anti-IFN-
c blocking antibody were also measured. IL-17 was highly
Th1 and Th17 Cells in EAE
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expressed in Th17 recipients whereas, in Th1 cells transfers, the
levels were close to control. This is in agreement with flow
cytometric analysis where IL-17 production was not observed in
the brain of Th1 cells recipient mice. Expression levels of IFN-c
were higher in Th1 recipients. Nevertheless, the fact that IFN-c
was also expressed in Th17 recipient mice confirmed the
phenotypic conversion of Th17 cells or de novo induction from
double negative cells in the CNS. Neutralization of IFN-c partially
Figure 1. MOG-specific Th1 and Th17 cell differentiation. A. T cells from 2D2 mice were activated under Th1 and Th17 polarizing conditions.
Va3.2 and Vb11 transgenic TCR chains, as well as intracellular IL-17 and IFN-c cytokine expression was assessed by FACS. Data shown are gated in the
CD4+ population. B. IFN-c and IL-17 cytokines from culture supernatants of Th1 and Th17 polarized cells were quantified by ELISA. C. IFN-c, Tbet, IL-17
and RORct gene expression was quantified by real-time PCR of Th1 and Th17 polarized cells. Data shown are representative (A) or a mean of a
minimum of 5 experiments. Error bars indicate SEM (B and C).
doi:10.1371/journal.pone.0015531.g001
Th1 and Th17 Cells in EAE
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suppressed the IFN-c expression while increasing IL-17 expression
in the CNS (Figure 4B). To determine whether Th1 and Th17
polarizing cytokines, such as IL-12 and IL-23 respectively, released
by innate immune cells could have a role in Th17 cells plasticity,
Th17 cells were transferred into Rag22/2 6 IL-12p352/2
(deficient of IL-12) and Rag22/26 IL-12p402/2 recipient mice
(deficient of both IL-12 and IL-23). In both cases, IFN-c
production by the host would be compromised and phenotypic
conversion might not happen. Contrary to our expectations, all
these mice developed EAE albeit with delayed EAE onset and
Th17 cells converted to IFN-c producing cells (Figure S1).
Cytotoxic ability of Th1 and Th17 cells towards astrocytes
During CNS autoimmunity, T cells that invade the CNS are
thought to be reactivated by local antigen presenting cells such as
astrocytes. Indeed, several studies suggest that astrocytes can
present antigen to the invading T cells, and in vitro co-culture of
astrocytes with activated myelin-specific T cells (primarily Th1
cells) can lyse those astrocytes presenting myelin peptides [18].
Further, highly activated astrocytes are common components of
MS lesions and death of astrocytes can be unfavourable re-
myelination processes.
Th1 and Th17 cells, driven by IL-12 and IL-23 respectively,
show distinct gene expression profile, which determine their
functional capabilities. Microarray analysis of Th1 and Th17 cells
by us (unpublished data) and others showed differential expression
of cytotoxicity-related molecules in these two subsets [19]. In our in
vitro polarized T cells, granzyme B was up-regulated in Th1 cells in
relation to Th17 cells and naı¨ve cells, and Fas-L expression was
down-regulated in Th17 cells. Both Th1 and Th17 cells showed
Figure 2. Comparative characterization of MOG-specific Th1, Th2 and Th17 cells. T cells from 2D2 mice were activated under Th1 and Th17
polarizing conditions. A. IL-4, IL-5, IL-10 and GM-CSF cytokines from culture supernatants of Th1, Th2 and Th17 polarized cells were quantified by
ELISA (A and B). B. GM-CSF gene expression of Th1 and Th17 polarized cells was quantified by real-time PCR. C. CD25 and CD62L surface expression
was assessed by FACS and represent the mean percentage of positive cells in the CD4+ population; **p,0.01; ***p,0.001. D. Antigen specific
proliferation of differentiated Th1 and Th17 cells with titrated concentrations of rMOG was measured by quantification of radioactive 3H-thymidine
uptake. *p,0.05; **p,0.01. Data shown are expressed as mean 6 SEM of 3 (A, B), 9 (C) or representative of 3 (D) independent experiments.
doi:10.1371/journal.pone.0015531.g002
Th1 and Th17 Cells in EAE
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lower perforin expression than naı¨ve T cells (Figure 5). Based on
these findings, and to learn more about the differential pathogenic
mechanisms mediated by Th1 and Th17 cells, we explored the
cytotoxic potential of these distinct CD4+ T cell lineages. We
investigated whether Th1 and Th17 cells possess the ability to lyse
autoantigen-presenting astrocytes. Astrocytes were pre-treated
with IFN-c and TNF-a to up-regulate MHC class II expression
on the surface (Figure 6A) and further co-cultured with T cells
for 48 hours. We observed massive cytolysis of astrocytes induced
by Th1 cells but not by Th17 cells. Blocking MHC class II only
moderately suppressed the cytotoxicity by Th1 cells probably due
to the modest up-regulation of MHC class II or by the highly
activated nature of the T cells that were co-cultured (Figures 6B,
C Videos S2, S3). ELISA analysis of the co-culture supernatants
showed that the extent of cytotoxicity might be correlated with the
amount of IFN-c produced by the Th1 cells, which is partially
suppressed by MHC class II blocking (Figure 6D). The addition
of supernatant from the Th1 cultures, which contain abundant
amounts of IFN-c failed to induce cytolysis of astrocytes indicating
a possible cell-to-cell contact mediated mechanism responsible for
the cytotoxicity (Figure 7A, Video S4). However, blocking IFN-
c did not prevent the cytotoxicity mediated by Th1 cells. Further,
neither the anti-Fas-L antibody nor the inhibitors of granzyme B
and pan-caspase (ZVAD) inhibitors prevented Th1-mediated
astrocyte lysis (Figure 7B, Videos S5, S6).
Since MHC class II expression was only moderately increased
after stimulation, to evaluate the role of antigen presentation in
Th1-mediated cytotoxicity, we performed T cell co-culture
experiments with FT7.1 cells, a L cell fibroblast cell line stably
transfected with the I-Ab molecule [20] (Figure 8A). Again, we
observed a massive cell death induced by Th1 cells and a
moderate cytolysis by Th17 cells. MHC class II blocking almost
completely prevented death of FT7.1cells in all cases (Figure 8B,
C, Video S7, S8). Intriguingly, Th17 cells also lysed FT7.1 cells
albeit to a lower extent and delayed kinetics. Interestingly,
quantification of IFN-c and IL-17 in the co-culture supernatants
revealed the presence of IFN-c in addition to IL-17 in Th17 cells
co-cultures suggesting a phenotypic conversion of Th17 cells to
Th1 which might be responsible for the cytotoxicity (Figure 8D).
In addition, IFN-c blocking partially prevented death of FT7.1
cells mediated by Th1 and Th17 cells (data not shown).
Altogether, these data suggest a cell-to-cell contact dependent
cytotoxic capacity of Th1 but not Th17 cells towards antigen
presenting fibroblasts and astrocytes. Moreover, these data
Figure 3. Adoptive transfer EAE with polarized Th1 and Th17 cells. Th1 and Th17 polarized cells were adoptively transferred to Rag22/2
recipient mice, either alone or in combination or with anti-IFN-c treatment as indicated. Recipient mice were scored for EAE disease. A. Shown is the
percentage of EAE incidence in the different recipient mice. ***p,0.0001; Th1+Th17 vs. all other conditions. B. EAE clinical scores in the different
recipient mice. Data is represented as mean 6 SD. C. Incidence of classical and atypical EAE phenotype in different T cell transfers. Shown is the
percentage of classical vs. atypical EAE incidence in the different recipient mice. Th1: n = 29; Th17: n = 40; Th1+Th17: n = 16; Th17+ anti-IFN-c: n = 11.
doi:10.1371/journal.pone.0015531.g003
Th1 and Th17 Cells in EAE
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demonstrate that in vitro generated Th17 cells are plastic and
convert to Th1 cells when recognize their cognate antigen,
supporting our data about in vivo Th17 plasticity in our EAE
model.
Discussion
Depending on the major cytokines produced, CD4+ T cells have
been classified into distinct subsets namely Th1, Th2, Th17, Th9,
Tfh and Treg. Recently, numerous studies were undertaken to
identify the T cell subset(s) primarily driving tissue-specific
autoimmune diseases, such as EAE. They showed that, in
principle, both Th1 and Th17 cells have the potential to mediate
autoimmune pathogenesis, though through different pathological
phenotypes [21–25].
Here, we compared the functional and pathogenic abilities of
Th1 and Th17 helper CD4+ T cell subsets derived from TCR
transgenic ‘‘monoclonal’’ T cells that recognize MOG and NF-M
peptides in the context of I-Ab. We used ‘‘monoclonal’’ T cells
from 2D2 TCR transgenic mice to rule out functional variations
due to different TCR repertoires. We optimized a protocol that
allowed us to generate sufficient numbers and purity of these
defined reactive cells and used them for adoptive transfer into
Rag2-deficient mice. Our data agree with recent studies [24,26]
that both Th1 and Th17 cells alone are capable of mediating EAE.
Furthermore, we show that Th1 and Th17 together synergize to
enhance disease severity and pathology.
The polarized Th1 and Th17 cells produced abundant amounts
of their signature cytokines, IFN-c and IL-17 respectively. In
addition, Th1 cells but not Th17 cells produced GM-CSF which is
in agreement with a recent study [27]. Although IL-23 can induce
the expression of GM-CSF in many innate cells, for unknown
reasons, our defined culture conditions did not allow GM-CSF
production by Th17 cells. Th1 but not Th17 cells readily
upregulated the surface expression of CD25, the IL-2 receptor
alpha chain commonly associated with the activation status of T
cells. Recent studies suggest that IL-2 acts as a negative regulator
of Th17 differentiation [28]. We speculate that Th17 cells do not
upregulate CD25 to avoid any inhibition rendered by IL-2.
Moreover, we added IL-23 but not IL-2 into our Th17
differentiation conditions which may further suppress CD25
expression.
The clinical EAE syndromes caused by Th1 and Th17 cells
were notably distinct. While transfer of Th1 cells alone induced a
classical EAE phenotype, characterized by an ascending caudo-
cranial paralysis. In contrast, approximately half of the Th17 cells
recipient mice developed atypical EAE with an ataxic gait
disturbance, reminding of an EAE variant described by Stromnes
et al in C3H mice immunized with MOG peptides. There, higher
Th17 cell numbers led to inflammation in the brain and an
atypical EAE, while Th1 skewing induced classic EAE [25].
Unexpectedly, the distinct clinical syndromes were not reflected by
macroscopic distributions of the lesions, but there were histological
distinctions. While lesions of Th1 recipients were dominated by
Th1 cells, Th17 recipients had infiltrates composed of both IFN-c
and IL-17 producing T cells. We speculate that transient high local
concentration of IL-17 in the brain might be responsible for the
atypical EAE presentation. However, due to the emergence of
IFN-c producing T cells in Th17 recipients, lesions might spread
throughout the CNS and remain indistinguishable between
recipients leading to classical EAE. In fact, we observed that
some Th17 recipients that presented ataxic disease progressed into
classic paralytic EAE. Interestingly, all of the Th1+Th17 co-
transfer mice developed only classical EAE demonstrating a
dominant effect of IFN-c on the disease outcome. This is in line
with the previous finding that IFN-c and its responsiveness of the
CNS determine the lesion localization [29,30].
The emergence of Th1-like cells in lesions initiated by
transferred IL-17 producing Th17 cells could be explained by
several mechanisms. Most prominently, Th1 cells could have
emerged from the numerous neutral cells contained in the
transferred inocula, or there might have been a shift from IL-17
to IFN-c production. Previous studies of highly purified cells
documented a high degree of plasticity of Th17 cells readily
Table 1. Quantification of inflammation and demyelination in spinal cord, brain and PNS.
Adoptive transfer EAE EAE score SC Inf SC DM Brain Inf Brain DM PNS
Th1 3.5 0.7 1 Cer, Obl, ON Cer:1, Obl: 1, ON:0 TG
3.5 0.5 1 Cer, Obl, Cer 3; Obl 1, TG
3.5 1.9 2 Cer, Obl, ON Cer 2, Obl 1, ON 1 TG
4 2.1 1 ON ON 1 TG, RO
4 3.5 2 Cer, ON Cer 1, ON 1 TG, RO
4 2.8 2 Cer, Obl, Trig, ON Cer 1, Obl 1, ON 1 TG, RO
Th17 4 2 2 Cer, obl Cer 2 TG
4 1.7 2 Cer, Obl, ON, ON 1 TG, RO
4 2.4 2 Cer, Obl, Trig Trig 2 TG, RO
ataxic 4.5 2 Cer, Obl, Trig, ON Cer 2, Obl 1, Trig 3, ON 1 TG
ataxic 1.3 1 Cer, Obl, Trig, ON Cer 1, Obl 1, ON 2 TG, RO
Th1+Th17 4 2.2 3 Cer, Obl, ON, ON 1 TG, RO
4 2.2 2 Obl, Trig, ON ON 1, Trig 2 TG, RO
4 2 3 Cer, Obl, ON, Trig ON 2, Trig 2 TG, RO
This quantification is according with the classification developed by [53]. SC Inf – inflammatory infiltrates per spinal cord section; SC DM – spinal cord extent of
demyelination determined semi-quantitatively: 1-perivenous, 2-confluent, 3-profound (half of spinal cord section), 4-complete (entire spinal cord section); Brain Inf and
Brain DM – Areas of the brain with inflammation and demyelination (with score as in SC): Cer-cerebellum, Obl-medulla oblongata, ON-optic nerves, Trig-central portion
of the trigeminal root; PNS – inflammation in the peripheral nervous system: TG-trigeminal root, RO-spinal roots.
doi:10.1371/journal.pone.0015531.t001
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Figure 4. Plasticity of Th17 cells in adoptive transfer EAE. Th1, Th17, Th1+Th17 cells or Th17 cells and anti-IFN-c antibodies were adoptively
transferred into Rag22/2 mice. A. EAE sick mice with classical EAE, minimum score of 3 were sacrificed, and brain and spleen were removed. Immune
cells were isolated and characterized for IFN-c and IL-17 expression by intracellular FACS staining. Data shown is gated in the CD4+ population and is
representative of a minimum of 5 animals analyzed per group. B. Expression of IFN-c and IL-17 in the brain from EAE sick mice was analyzed by real
time PCR. Rag22/2 control: n = 7; Th1: n = 7; Th17: n = 10; Th1+Th17: n = 5; Th17+anti-IFN-c: n = 6. Data are represented as mean 6 SEM. *p,0.05;
***p,0.0001.
doi:10.1371/journal.pone.0015531.g004
Figure 5. Cytotoxic molecules expression by Th1 and Th17 cells. T cells from 2D2 mice were activated under Th1 and Th17 polarizing
conditions. Expression of granzyme B, Fas-L and perforin in naive T cells (n = 4), Th1 (n = 6) and Th17 cells (n = 7) were measured by real time PCR. The
data is represented as mean 6 SEM.
doi:10.1371/journal.pone.0015531.g005
Th1 and Th17 Cells in EAE
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converting to Th1 phenotype in vivo, a process particularly
prominent in the lymphopenic recipients [31,32]. We used
Rag22/2 mice as recipients to avoid any host derived cells
contributing to the pathogenesis [33] and this could have
facilitated phenotype conversion. Converted IFN-c producing
Th1 cells were found both in the CNS and in the periphery and it
equalled the numbers of IL-17 producing Th17 cells. Interestingly,
in contrast to the previous studies [31,32], we found IFN-c+IL-17+
cells only in the CNS, not in peripheral lymphoid organs,
suggesting a specific milieu or re-activation inside the CNS
furthering the conversion to double cytokine producing T cells.
Since host derived IFN-c might antagonize the maintenance of IL-
17 phenotype [34], we neutralized the IFN-c in vivo by blocking
antibodies. However, IFN-c neutralization neither affected clinical
disease nor phenotypic conversion of Th17 cells but partially
suppressed IFN-c related gene expression in the CNS. This could
be due to the maximal activation of T cells before transfer or,
more trivially, the exclusion of sufficient doses of antibodies from
the CNS. In vitro, we observed conversion of Th17 cells to the Th1
phenotype only after renewed encounter with the antigen. Also,
locally formed IL-12, the master cytokine inducing IFN-c
production in naı¨ve CD4+ T cells, could have supported the
conversion of Th17 cells [35]. However, unexpectedly, Th17 cells
induced EAE in both IL-12p35 deficient (lacking IL-12 solely) and
in IL-12p40 deficient mice (lacking both IL-12 and IL-23 and, in
both hosts, we noted conversion of Th17 cells into IFN-c
producers. Recently it has been reported that a minor subset of
Th17 cells can convert to IFN-c producers in the absence of IL-12
in vitro [36]. We speculate that yet unknown factor(s), independent
of IL-12, IL-23 might induce phenotypic conversion in vivo.
Finally, it is possible that infiltrating Th17 cells or IFN-c2IL-172
cells that, in the CNS, local antigen-presenting cells such as
astrocytes or microglia could have driven T cells from an IL-17 to
IFN-c production. Our data thus indicate a one-way phenotype
conversion from IL-17- to IFN-c producer but not vice-versa. The
distinct clinical outcomes may be dependent on the extent of in vivo
conversion of Th17 to the Th1 phenotype. In line with this, a
recent report suggested that Th17 cells induced diabetes only upon
conversion into IFN-c producers in vivo [37].
Do Th1 and Th17 T cell subsets differ in their effector
mechanisms? Distinct cytokine and chemokine expression by these
cell types likely contribute to the differential migration and effector
Figure 6. Cytotoxic potential of Th1 and Th17 cells towards astrocytes. 2D2 MOG-specific T cells were polarized in Th1 and Th17 conditions
and co-cultured in duplicates with activated astrocytes as described in methods. A. MHC class II expression on astrocytes was analysed by FACS. B.
GFP-labeled astrocytes were co-cultured with Th1 or Th17 cells in the presence of isotype control or anti-MHC class II antibodies. Cells were tracked
every 30 minutes by fluorescent time-lapse microscopy. Shown is the snap-shot fluorescent picture after 48 h co-culture. Magnification: 106. C.
Quantification of the fluorescent area (surviving cells) every 6 hours in the conditions shown in B. The values were normalized to that of control
(astrocytes only). D. IL-17 and IFN-c levels were measured in the supernatants at 48 h after the co-culture by ELISA. Data shown are representative of
minimum 3 experiments. *p,0.05; ns-not significant.
doi:10.1371/journal.pone.0015531.g006
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mechanisms at the target organ thus leading to different clinical
outcomes. It is known that Th1 cells induce the expression of
MHC class II or adhesion molecules on APCs by virtue of the
production of IFN-c, and thus facilitate the migration of T cells
into CNS [38–41], activate macrophages [42] and induce Tregs
[43]. On the other hand, Th17 cells producing IL-17A, IL-17F,
IL-21 and IL-22, attract neutrophils to the site of inflammation
[44], promote host defense [34] and regulate Tregs [45]. We
found another principal difference between Th1 and Th17 effector
T cells. Old work predating the identification of CD4+ T cell
subsets discovered that the encephalitogenic T cells lyse myelin
antigen presenting astrocytes [18,46–48]. Indeed, we show here
that our Th1 polarized cells lyse antigen presenting astrocytes and
the fibroblasts. We used neutralizing antibodies to test the
potential involvement of several lysis-related molecules (including
IFN-c MHC class II, granzyme B, caspases and FasL) in Th1-
mediated cytotoxicity. None of them, with the exception of
antibodies against MHC class II and IFN-c, substantially blocked
Th1 cell cytotoxicity. Whether this represents a yet unknown, cell-
to-cell contact mediated mechanism potentiated by IFN-c and
antigen presentation remains to be shown. In contrast, Th17 cells
failed to kill astrocytes and fibroblasts but acquired cytotoxic
potential after converting to IFN-c producing Th1 phenotype.
Our future studies will address whether cytotoxic damage to
astrocytes by Th1 autoimmune effector cells have a role in vivo. In
addition to their supportive role in the CNS, astrocytes are
activated in MS lesions and upregulate MHC class II to a certain
degree [49]. Astrocyte targeted autoimmunity could also have a
pathological consequence. Similar to neuromyelitis optica (NMO)
where specific autoantibodies kill aquaporin-4 expressing astro-
cytes, a cytotoxic attack of myelin presenting astrocytes could
contribute to the pathology in optic nerve and spinal cord of EAE
and MS lesions [50].
Materials and Methods
Mice
2D2 (TCRMOG)[17], TCRMOG 6 IgHMOG double transgenic
Optico-Spinal Encephalomyelitis (OSE) [15], Rag22/2, IL-
12p352/2, IL-12p402/2 and beta-actin GFP transgenic mice were
bred in the animal facilities of the Max Planck Institute of
Biochemistry and Neurobiology. All animals used in this study were
with C57BL/6 background. The protocol was approved by the
animal welfare committee of Government of Upper Bavaria
(Tierschutzkommission der Regierung von Oberbayern, Munich,
Germany) (License No: 55.2-1-54-2531-45/04). The animal proce-
dures were in strict accordance with the guidelines set down by the
animal welfare committee of the Government of Upper Bavaria.
In vitro CD4+ T cell differentiation
Th1 and Th17 polarized cells were obtained after optimization
of protocols described previously [51,52]. Briefly, 206106 OSE or
Figure 7. Effect of blockade of cytotoxic molecules on Th1 mediated astrocyte cytotoxicity. 2D2 MOG-specific Th1 cells were co-cultured
in duplicates for 48 hours with astrocytes in the presence or absence of the Th1 culture supernatant (A), anti-IFN-c antibody, anti-FasL antibody,
Granzyme B (GzmB) inhibitor and the pan-caspase inhibitor ZVAD (B). Cells were tracked every 30 minutes by fluorescent time-lapse microscopy.
Shown is the snap-shot fluorescent picture at the end of the culture period and is representative of minimum 2 experiments.
doi:10.1371/journal.pone.0015531.g007
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2D2 total erythrocyte-lysed spleen cells per well were cultured for
6 days in the presence of 20 mg/ml rMOG (MOG aa1-125) in 6
well-plates in complete RPMI-1640 with 10% FCS. For Th1 and
Th17 polarization, the following cytokines and antibodies were
further added in the culture. Th1: IL-12 (10 ng/ml), IL-18
(25 ng/ml) and anti-IL-4 (10 mg/ml); Th17: human TGF-b1
(5 ng/ml), IL-6 (20 ng/ml), IL-23 (10 ng/ml), anti-IL-4 (10 mg/
ml) and anti-IFN-c (10 mg/ml); Th2: IL-4 (50 ng/ml) and anti-
IFN-c (10 mg/ml;. All cytokines were purchased from Peprotech
except IL-23 (R&D Systems) and IL-18 (MBL). The neutralizing
antibodies were produced from hybridoma supernatants. Th1 cells
were supplemented with IL-2 (10 ng/ml, Peprotech) and Th17
cells with IL-23 (10 ng/ml) at day 3 of culture. 5–6 days later,
living cells were purified by Nycoprep (Axis-Shield) gradient and
CD4+ T cells were isolated by negative selection (R&D Systems)
according to manufacturer’s instructions. Purified CD4+ T cells
(approximately 56106 cells/well) were polarized for a second time
in the same conditions and in the presence of irradiated (30 Gy)
splenic antigen presenting cells for additional 3 days. Activated
living cells were purified by Nycoprep, yielding .99% pure CD4+
population.
T cell proliferation assay
MOG-specific CD4+ T cells previously differentiated in Th1
and Th17 polarizing conditions were re-stimulated in triplicates
(46104 T cells/well) in the presence of irradiated splenic cells
(26105 cells/well) and rMOG for 72 h. Antigen specific T cell
proliferation was measured by adding 1 mCi of [3H]-thymidine in
the last 18 h and incorporated radioactivity was measured in the
Beta counter.
Adoptive transfer EAE
Freshly activated MOG-specific CD4+ Th1 and Th17 cells were
suspended in PBS, counted and injected intravenously into
Rag22/2 recipient mice. Each animal received 5 to 106106 of
Th1, Th17 or mixed Th1 and Th17 cells (proportion of 1:2). In
one group of Th17 cells transfer, anti-IFN-c antibodies (500 mg/
mouse) were injected at 4 days interval. Animals were evaluated
every 1–2 days for clinical symptoms. The classical EAE scores
were given as below: score 0 – no disease; score 0,5 – reduced tail
tonus; score 1: limp tail; score 1,5 – limp tail and ataxia; score 2 –
limp tail, ataxia and hind limb weakness; score 2,5 – at least one
hind limb paralyzed/weakness; score 3 – both hind limbs
Figure 8. Cytotoxic potential of Th1 and Th17 cells towards FT7.1 cells. 2D2 MOG-specific T cells were polarized in Th1 and Th17 conditions
and co-cultured in duplicates with FT7.1 cells as described in methods. A. MHC class II expression on FT7.1 cells was analysed by FACS. B. GFP-labeled
FT7.1 cells were co-cultured with Th1 or Th17 cells in the presence of isotype control or anti-MHC class II antibodies. Cells were tracked every 30
minutes by fluorescent time-lapse microscopy. Shown is the snap-shot fluorescent picture after 48 h co-culture. Magnification: 106. C. Quantification
of the fluorescent area (surviving cells) every 6 hours in the conditions shown in B. The values were normalized to that of control (FT7.1 cells only). D.
IL-17 and IFN-c levels were measured in the supernatants at 48 h after the co-culture by ELISA. Data shown are representative of minimum 3
experiments. ns-not significant.
doi:10.1371/journal.pone.0015531.g008
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paralyzed/weakness; score 3,5 –complete paralysis of hind limbs;
score 4 – paralysis until hip; score 5 – moribund or dead. The non-
classical (atypical) EAE scores were given as follows: score 0 – no
disease; score 1 – head turned slightly (ataxia, no tail paralysis);
score 2 – head turned more pronounced; score 3 – inability to walk
on a straight line; score 4 – laying on side; score 4,5 – rolling
continuously unless supported; score 5 – moribund or dead.
Mononuclear cells isolation from CNS tissue
Sick mice were perfused transcardially with PBS. Spinal cord
and brain tissue were isolated and homogenized in RPMI-1640
medium. Brain and spinal cord suspensions were passed through a
40 mm nylon mesh (BD Biosciences) and centrifuged. Cells were
re-suspended in 30% percoll (GE Healthcare), overlaid on 70%
Percoll and centrifuged for 20 min at 1200 g at room temperature.
After centrifugation, the interface containing mononuclear cells
was removed, washed with RPMI and used for flow cytometry.
Flow cytometry
Single cell suspension of spleen and lymph nodes were prepared
by nylon mesh. CNS infiltrating mononuclear cells were isolated
by Percoll gradient. For intracellular cytokine staining, cells were
stimulated for 4 hours with PMA (50 ng/ml), ionomycin (0.5 mg/
ml) and brefeldin A (5 mg/ml) (Sigma Aldrich). Cells were first
stained extracellularly in FACS buffer with fluorochrome labeled
rat anti-mouse CD3e (145-2C11), CD4 (RM4-5), Va3.2 TCR
(RR3-16), Vb11 (RR3-15), CD25 (PC61) and CD62L (MEL-14)
antibodies (all from BD Pharmingen except CD62L, from
Immuno Tools). Stained cells were washed, then fixed and
permeabilized with 2% PFA and saponin buffer and finally stained
intracellularly with anti-IFN-c (XMG1.2) and anti-IL-17 (TC11-
18H10) (BD Pharmingen) and their respective isotype controls in
saponin buffer. Astrocytes and FT7.1 cells were stained with anti-
MHC class II (2G9). Samples were acquired on a FACSCalibur
(BD Biosciences) and data were analysed with CellQuest (BD
Bioscience) and Flow Jo version 7.2.5 (Tree Star) softwares.
Enzyme linked immunosorbent assay (ELISA)
Cytokine production was determined by ELISA using matching
antibody pairs for IFN-c (purified capture antibody clone AN-18,
biotinylated detection antibody clone XMG1.2, BD Pharmingen),
IL-17 (purified capture antibody clone eBio17CK15A5, biotiny-
lated detection antibody clone eBio17B7, eBioscience), IL-4
(purified capture antibody clone BVD4-1D11, biotinylated
detection antibody clone BVD6-24G2, BD Pharmingen), IL-5
(purified capture antibody clone TRFK5, biotinylated detection
antibody clone TRFK4, BD Pharmingen), IL-10 (R&D Systems)
and GM-CSF (Peprotech) according to the manufacturer’s
instructions. Culture supernatants were collected and frozen at
220uC until quantification.
Quantitative real-time PCR analysis
Total RNA was isolated with TRI Reagent extraction (Sigma-
Aldrich). 1–4 mg of RNA was treated with DNase I and then
reverse transcribed into cDNA using oligo-dT primers and
SuperScript II Reverse Transcriptase (Invitrogen), according to
manufacturer’s instructions. Primers and probes (Table S1)
(Metabion, Martinsried, Germany) were used for SYBR Green or
TaqMan PCR analysis. Where possible, the primer/probe
sequence combinations spanned contact sequences of subsequent
exons. For amplification, the Absolute QPCR mix was used
(ABgene). Each reaction was run in triplicate on an ABI 7900
machine (Applied Biosystems) and was normalized to housekeeping
gene GAPDH transcripts. Primary data was analyzed with Gene-
Amp SDS version 2.3 software (Applied Biosystems).
Histological analysis
Animals were perfused with cold PBS and then with 4%
paraformaldehyde in PBS, stored in the same fixative for 24 hours
at 4uC, washed twice with PBS, and finally kept at 4uC until used.
Brain and spinal cord tissue was dissected and in part embedded in
paraffin, or snap frozen in Tissue Tek OCT compound on dry ice
for immunohistochemistry. Adjacent serial sections were stained
with hematoxylin (H&E), luxol fast blue (LFB), or Bielschowsky
silver impregnation (Biel).
Astrocytes primary culture
Primary astrocyte cell cultures were obtained from 2-days-old
beta-actin GFP transgenic or wild type C57BL/6 mouse pups.
Briefly, brains were removed, placed in 15 mM of Hepes in Hanks
Balanced Salt Solution (HBSS) (Gibco) and meninges were
removed. Brains were homogenized in 15 mM of Hepes in HBSS
with 1 ml tip and a 27 G syringe and cells were dissociated with
incubation at 37uC for 10 minutes in 2 mg/ml of trypsin solution.
After washing, cells were suspended in supplemented DMEM
(Gibco), passed through a 70 mm cell strainer, and plated in a T75
flask. Cells were allowed to grow for 8 to 10 days and media was
changed every 3 days. Cells were shaken overnight at 90 rpm to
remove contaminating oligodendrocytes, microglia and neurons.
Adherent cells contain a majority of astrocytes whose purity was
increased with trypsinization and further passages. Experiments
were done with astrocytes with a minimum of 2–3 passages.
FT7.1 cell line culture
The fibroblast cell transfectants FT7.1, which overexpress the
mouse I-Ab MHC class II molecule on their surface, were cultured
in supplemented RPMI media plus the selective reagents:
mycophenolic acid (2.5 mg/100 ml), xanthine (25 mg/100 ml)
and hypoxanthine (2.5 mg/100 ml) (Sigma). For the use in time-
lapse fluorescent microscopy experiments, FT7.1 cells were
retrovirally transduced with GFP (pMSCVneo-IRES2-eGFP).
T cells and astrocytes or FT7.1 cells co-culture.
2 days before the co-culture, primary GFP-astrocytes were
trypsinised, irradiated with 30 Gy and plated 46104 cells per well
in 96-well plate. On the following day, adherent astrocytes were
stimulated with IFN-c and TNF-a, 10 ng/ml each (Pepro-
tech).GFP-FT7.1 cells were plated (2.56104 cells per well) in 96-
well plate. Freshly activated T cells were added to stimulated
astrocytes or FT7.1 cells in a ratio of 1:10, in the presence of
20 mg/ml MOG 35–55 peptide. The following blocking antibodies
and inhibitors were used: 10 mg/ml anti-MHC class II (2G9),
10 mg/ml anti-IFN-c (R4-6A2), 10 mg/ml anti-Fas-L, 10 mg/ml
isotype control IgG2a (all from BD Pharmingen), 25 mM
Granzyme B inhibitor II (Calbiochem) and 25 mM caspase
inhibitor Z-VAD (Calbiochem). Cytotoxicity was evaluated by
fluorescent time-lapse microscopy for 48 h using the MetaMorph
software (Molecular Devices). For quantification, area covered by
the fluorescent intact cells was calculated after background
correction for each image using ImageJ. The data were
normalized to that of control for each time point.
Statistics
Descriptive statistical analysis was performed using Prism
version 5 software (GraphPad). Differential EAE incidence was
analyzed by log-rank (Mantel-Cox) test by an in-built survival
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curve analysis. One- and two-way ANOVA and t test statistical
analysis were used in the other studies. p values less than 0.05 were
considered to be significant.
Supporting Information
Figure S1 Adoptive transfer EAE of polarized Th17 cells
in mice deficient of IL-12p35 or IL-12p40. A. In vitro
polarized Th17 cells were adoptively transferred to Rag22/2,
Rag22/26 IL-12p352/2 and Rag22/26 IL-12p402/2 mice as
described in methods. Recipient mice were scored for EAE
disease. Shown is the evaluation of percentage of EAE incidence in
the different recipient mice. *p,0.001 in Rag22/2 vs. other
conditions. n = 5 animals per group. B. CNS infiltrating cells were
isolated from sick mice of the above adoptive transfer and
characterized for IFN-c and IL-17 expression by intracellular
FACS staining. Data shown is gated in the CD4+ population.
(TIF)
Figure S2 Histological analysis of Th1 and Th17 cells
recipient mice. Spinal cord sections of Rag22/2 recipient mice
were characterized by histology and immunohistochemistry. H&E
– haematoxylin & eosin, LFB – Luxol Fast Blue, Biel –
Bielschowsky, CD3- for T cells, and MAC3 is a marker for
phagocytes. Magnification: 256. Representative figures are
shown. Th1: n = 6; Th17: n = 5; Th1+Th17: n = 3.
(TIF)
Video S1 Different EAE clinical phenotypes induced by
Th1 and Th17 cells. Shown is Th1 cells recipient mice with
classical EAE, score 3 - tail and both hind limbs paralyzed (left);
and Th17 cells recipient mice with atypical EAE, score 3.5 -
inability to walk on a straight line and laying on side (right).
(WMV)
Video S2 Th1 but not Th17 cells lyse astrocytes. GFP-
positive astrocytes were co-cultured with Th1 or Th17 cells for
48 h in the presence of isotype control antibody. Cells were
tracked every 30 minutes by fluorescent time-lapse microscopy.
(AVI)
Video S3 Th1 but not Th17 cells lyse astrocytes. GFP-
positive astrocytes were co-cultured with Th1 or Th17 cells for
48 h in the presence of MHC class II blocking antibody. Cells
were tracked every 30 minutes by fluorescent time-lapse
microscopy.
(AVI)
Video S4 Effect of blockade of cytotoxic molecules on
Th1 mediated astrocyte cytotoxicity. GFP-positive astro-
cytes were co-cultured with Th1 cells or Th1cell culture
supernatants for 48 h. Cells were tracked every 30 minutes by
fluorescent time-lapse microscopy.
(AVI)
Video S5 Effect of blockade of cytotoxic molecules on
Th1 mediated astrocyte cytotoxicity. GFP-positive astro-
cytes were co-cultured with Th1 cells with and without the
presence of anti-IFN-c antibody for 48 h. Cells were tracked every
30 minutes by fluorescent time-lapse microscopy.
(AVI)
Video S6 Effect of blockade of cytotoxic molecules on
Th1 mediated astrocyte cytotoxicity. GFP-positive astro-
cytes were co-cultured with Th1 cells in the presence of anti-FasL
antibody, Granzyme B (GzmB) inhibitor or the pan-caspase
inhibitor ZVAD for 48 h. Cells were tracked every 30 minutes by
fluorescent time-lapse microscopy.
(AVI)
Video S7 Cytotoxic potential of Th1 and Th17 cells
towards FT7.1 cells. MHC class II overexpressing GFP-
positive FT7.1 cells were co-cultured with Th1 or Th17 cells for
48 h in the presence of isotype control antibody. Cells were
tracked every 30 minutes by fluorescent time-lapse microscopy.
(AVI)
Video S8 Cytotoxic potential of Th1 and Th17 cells
towards FT7.1 cells. MHC class II overexpressing GFP-
positive FT7.1 cells were co-cultured with Th1 or Th17 cells for
48 h in the presence of MHC class II blocking antibody. Cells
were tracked every 30 minutes by fluorescent time-lapse
microscopy.
(AVI)
Table S1 Primers and probes used for real-time PCR.
(DOC)
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